New drug aims to cut heart risk for patients with high lp(a) after heart attack

NCT ID NCT07625306

Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called pelacarsen in people who recently had a heart attack and have high levels of Lp(a), a type of fat in the blood that raises heart risk. The goal is to see if the drug can safely lower Lp(a) levels and improve heart health. About 240 adults in the US will take either the drug or a placebo, and researchers will check their blood and heart arteries over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME (ACS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.